Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 67 #1
TickerOHRP [NASD]
CompanyOhr Pharmaceutical, Inc.
CountryUSA
IndustryBiotechnology
Market Cap79.71MEPS (ttm)-0.49
P/E-EPS this Y-36.70%
Forward P/E-EPS next Y-46.60%
PEG-EPS past 5Y-32.60%
P/S-EPS next 5Y-
P/B3.08EPS Q/Q-80.00%
Dividend-Sales Q/Q-
Insider Own1.90%Inst Own21.00%
Insider Trans7.98%Inst Trans1.78%
Short Float9.36%Earnings-
Analyst Recom1.80Target Price27.25
Avg Volume324.83K52W Range6.01 - 14.60
Mar-27-15Downgrade Chardan Capital Markets Buy → Neutral $20 → $8
Mar-27-15 04:45PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OHR PHARMACEUTICAL, INC. -- OHRP PR Newswire
Mar-27-15 02:02PMAnalyst Discounts Chances For OHR Pharmaceutical Eye Drug
Mar-27-15 12:50PMEQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Ohr Pharmaceutical, Inc. OHRP Business Wire
Mar-27-15 11:29AMOhr Pharmaceuticals (OHRP) Stock Tanks Today Following Disappointing Test Results at TheStreet
Mar-27-15 09:28AMOhr Pharmaceutical's stock plunges on heavy volume after disappointing study results at MarketWatch
Mar-27-15 09:18AMOhr Pharma downgraded by Chardan Capital Markets
Mar-27-15 08:40AMOhr's eye drug fails mid-stage study, shares plunge 44 pct
Mar-27-15 08:39AMOhr Pharma's eye drug fails in mid-stage study, shares plunge
Mar-27-15 07:36AMOhr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD at noodls
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes. The company is evaluating OHR-102 eye drops in various Phase II studies for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. The company is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Slakter Jason ScottDirectorFeb 06Buy6.7529,630200,00364,573Feb 10 03:48 PM
Backenroth SamuelChief Financial OfficerFeb 06Buy6.751,50010,1256,199Feb 10 03:55 PM
Almenoff June SherieDirectorFeb 06Buy6.756,00040,50016,900Feb 10 12:46 PM
Taraporewala Irach B.Chief Executive OfficerFeb 06Buy6.753,70525,00922,800Feb 10 12:50 PM
Almenoff June SherieDirectorSep 03Buy8.051,2009,660127,566Sep 04 01:10 PM
TickerINPH [NASD]
CompanyInterphase Corp.
CountryUSA
IndustryComputer Peripherals
Market Cap14.58MEPS (ttm)-0.48
P/E-EPS this Y27.80%
Forward P/E-EPS next Y-
PEG-EPS past 5Y3.20%
P/S0.96EPS next 5Y30.00%
P/B1.72EPS Q/Q-
Dividend-Sales Q/Q0.00%
Insider Own0.60%Inst Own36.40%
Insider Trans-4.56%Inst Trans1.09%
Short Float0.03%EarningsMar 26/a
Analyst Recom-Target Price19.80
Avg Volume6.51K52W Range1.82 - 6.91
Mar-26-15 05:37PMInterphase Announces Fourth Quarter and 2014 Full Year Financial Results at noodls
Mar-26-15 04:42PMINTERPHASE CORP Files SEC form 8-K, Results of Operations and Financial Condition
Mar-26-15 04:30PMInterphase Announces Fourth Quarter and 2014 Full Year Financial Results Business Wire
Mar-26-15 07:07AMQ4 2014 Interphase Corp Earnings Release - After Market Close
Mar-25-15 02:27PMpenveu® Announces New HDMI® Models at noodls
Mar-25-15 12:00PMpenveu® Announces New HDMI® Models Business Wire
Mar-18-15 10:18AMInterphase Schedules Fourth Quarter & Year End 2014 Earnings Call GlobeNewswire
Mar-17-15 07:55PMInterphase Schedules Fourth Quarter & End of Year 2014 Earnings Call at noodls
Mar-05-15 12:10PMpenveu to Exhibit at Several Spring Events at noodls
Interphase Corporation, an information and communications technology company, provides connectivity, interworking, and packet processing solutions in the Pacific Rim, North America, and Europe. The company's network connectivity products include T1/E1 communication controllers that primarily support SS7 signaling, OC-3/STM-1 asynchronous transfer mode network interface cards (NICs), and Ethernet NICs; interworking products comprise OC-3/STM-1 interworking modules, and broadband access gateway and media converters; and multi-core packet processors consist of Gigabit Ethernet (GigE) and 10 GigE packet processors. It also provides penveu, a handheld device primarily for the education market that adds interactivity to the installed base of projectors and large screen displays, making any flat surface, from pull down screens to HDTVs, an interactive display system. In addition, the company offers engineering design services, such as specifications gathering; program management; electrical, mechanical, and thermal design; wireless services design for cellular, WiFi, Bluetooth, and other services; mechanical enclosure design; software design for drivers and applications; application software porting and integration; rapid prototyping; and manufacturability and testability design, product design verification testing, product certification, and production test development. Further, it offers electronics manufacturing services comprising supply chain management, custom branding and control, production assembly, integration, testing and delivery, and inventory management and logistics services. The company sells its products and services to telecom equipment and server manufacturers, as well as to the electronics industry through its direct sales force, manufacturers' representatives, value-added distributors, and Web and social media tools. Interphase Corporation was founded in 1974 and is headquartered in Carrollton, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TIPTON THOMAS N JRCFO & VP of FinanceJan 13Sale2.279382,12929,343Jan 15 04:38 PM
Solomon YoramVP Corp. Strategy & Bus. Dev.Jan 13Sale2.277501,70317,544Jan 15 04:29 PM
MCCOMAS RANDALLVP of SalesJan 13Sale2.317171,6565,531Jan 15 04:21 PM
KALUSH GREGPresident & CEOMay 07Sale5.457604,142126,984May 08 04:22 PM
TickerMRVC [NASD]
CompanyMRV Communications, Inc.
CountryUSA
IndustryNetworking & Communication Devices
Market Cap51.83MEPS (ttm)-1.66
P/E-EPS this Y-82.40%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-24.70%
P/S0.30EPS next 5Y-
P/B1.05EPS Q/Q-270.60%
Dividend-Sales Q/Q-14.40%
Insider Own43.84%Inst Own34.90%
Insider Trans-1.50%Inst Trans-3.39%
Short Float0.01%EarningsMar 10/a
Analyst Recom-Target Price-
Avg Volume19.87K52W Range7.03 - 15.31
Mar-25-15 08:17AMMRV OptiDriver Platform Picks Up Additional Honor by Lightwave Innovation Awards at noodls
Mar-25-15 08:00AMMRVs Optical Channel Manager Expands OptiDriver Platform with Intelligent Wavelength Monitoring Capabilities Business Wire
Mar-24-15 01:04PMMRV COMMUNICATIONS INC Financials
Mar-23-15 10:51AMMRV OptiDriver Platform Picks Up Additional Honor by Lightwave Innovation Awards Business Wire
Mar-16-15 04:57PMMRV COMMUNICATIONS INC Files SEC form 10-K, Annual Report
Mar-11-15 08:04AMMRV Reports Fourth-Quarter and Full-Year 2014 Results at noodls
Mar-11-15 08:00AMMRV Introduces New Optical Programmability and Flexible Bandwidth Capacity Capabilities on the OptiDriver Platform Business Wire
Mar-10-15 04:40PMMRV to Announce Fourth-Quarter and Year-End 2014 Results at noodls
Mar-10-15 04:08PMMRV COMMUNICATIONS INC Files SEC form 8-K, Results of Operations and Financial Condition
Mar-10-15 04:05PMMRV Reports Fourth-Quarter and Full-Year 2014 Results Business Wire
MRV Communications, Inc. provides communications solutions to telecommunications service providers, enterprises, and governments worldwide. It operates in two segments, Network Equipment and Network Integration. The Network Equipment segment offers packet and optical solutions that enable access, aggregation, transport, and management of various communications traffic for fixed line, cable, content delivery, cloud-based, and mobile communications networks leveraging direct and channel sales through third party channel partners. This segment also develops optical edge solutions that combine packet and optical technologies, and network management software; infrastructure management solutions; and fiber optic modules for the fiber-optic communication industry. The Network Integration segment offers end-to-end solutions, including consulting, installation, and support and managed services for fixed line, cable, and mobile communications networks; and supplies a range of communications equipment, as well as provides telecommunications solutions consisting of network infrastructure, unified communications, mobility and wireless, network security, cloud computing services, managed call center services, network integration, and optimization serving the Italian market. MRV Communications, Inc. markets and sells its products through direct sales force, manufacturers' representatives, value-added-resellers, distributors, and systems integrators. The company was formerly known as MRV Technologies, Inc. and changed its name to MRV Communications, Inc. in April 1992. MRV Communications, Inc. was founded in 1988 and is headquartered in Chatsworth, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER LLOYD I IIIno longer 10% holderJan 15Sale11.0047,400521,4007,402Jan 20 02:10 PM
TickerNBS [NASD]
CompanyNeostem, Inc.
CountryUSA
IndustryBiotechnology
Market Cap106.51MEPS (ttm)-1.65
P/E-EPS this Y11.60%
Forward P/E-EPS next Y-4.00%
PEG-EPS past 5Y41.40%
P/S5.95EPS next 5Y-
P/B1.71EPS Q/Q31.90%
Dividend2.17%Sales Q/Q29.30%
Insider Own3.90%Inst Own17.20%
Insider Trans-3.52%Inst Trans-1.40%
Short Float7.13%EarningsMar 12/a
Analyst Recom1.70Target Price18.67
Avg Volume314.95K52W Range2.92 - 7.39
Mar-19-15 09:48AMNeoStem, Inc. - "CEO Letter to Shareholders" Accesswire
Mar-16-15 06:23AMNeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results at noodls
Mar-16-15 06:11AMNEOSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure
Mar-16-15 06:00AMNeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results GlobeNewswire
Mar-12-15 09:52AMNeoStem to Present at Two Upcoming Investor Conferences in March at noodls
Mar-12-15 07:30AMNeoStem to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Mar-05-15 07:30AMNeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of Cardiology Annual Scientific Session on March 15 GlobeNewswire
Mar-02-15 09:13PMNeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update at noodls
Mar-02-15 07:13PMNeoStem reports 4Q loss
Mar-02-15 04:08PMNEOSTEM, INC. Files SEC form 10-K, Annual Report
NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wei EricDirectorMar 18Sale3.20100,000320,0002,122,988Mar 20 09:00 PM
MYERS STEVEN SDirectorDec 09Buy3.4915,00052,40984,331Dec 09 09:00 PM
RimAsia Capital Partners, L.P.DirectorDec 09Sale3.5313,94049,2042,210,988Jan 02 09:00 PM
RimAsia Capital Partners ManagDirectorDec 08Sale3.7516,06060,2252,224,928Dec 09 09:00 PM
MYERS STEVEN SDirectorDec 05Buy3.755,00018,74569,331Dec 09 09:00 PM
TickerJMI [NYSE]
CompanyJAVELIN Mortgage Investment Corp.
CountryUSA
IndustryREIT - Diversified
Market Cap93.68MEPS (ttm)-1.81
P/E-EPS this Y53.50%
Forward P/E5.81EPS next Y2.98%
PEG-EPS past 5Y-8.91%
P/S-EPS next 5Y3.00%
P/B0.67EPS Q/Q65.20%
Dividend18.41%Sales Q/Q-
Insider Own0.50%Inst Own25.40%
Insider Trans102.02%Inst Trans10.53%
Short Float4.70%EarningsFeb 26/a
Analyst Recom3.40Target Price12.08
Avg Volume146.66K52W Range8.28 - 12.75
Mar-26-15 05:11PMJAVELIN MORTGAGE INVESTMENT CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-26-15 04:15PM4:15 pm Javelin Mortgage declares monthly dividend of $0.09/share vs. prior dividend of $0.12/share
Mar-26-15 04:05PMJAVELIN Mortgage Investment Corp. Announces Expected Monthly Dividend Rate for Q2 2015 GlobeNewswire
Mar-13-15 01:04PMJAVELIN MORTGAGE INVESTMENT CORP. Financials
Mar-09-15 10:57AMWebcast at noodls
Feb-26-15 05:22PMJAVELIN MORTGAGE INVESTMENT CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem
Feb-26-15 04:15PMJAVELIN Mortgage Investment Corp. Reports Q4 2014 Annualized ROE of 8.61% on Core and Estimated Taxable REIT Income of $3.3 Million GlobeNewswire
Feb-26-15 10:00AMJAVELIN Mortgage Investment Corp. Fourth Quarter Conference Call Scheduled For March 2, 2015 PR Newswire
Feb-13-15 04:54PMJAVELIN MORTGAGE INVESTMENT CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-27-15 04:40PMJAVELIN MORTGAGE INVESTMENT CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zimmer Jeffrey JCo-CEO and PresidentMar 11Buy8.545,00042,69421,775Mar 11 12:01 PM
ULM SCOTTCo-CEO and CIOMar 05Buy8.9510,00089,48622,525Mar 05 12:32 PM
Zimmer Jeffrey JCo-CEO and PresidentMar 03Buy8.885,25046,62016,775Mar 03 11:38 AM
Zimmer Jeffrey JCo-CEO and PresidentJan 07Buy9.895,00049,45411,525Jan 07 12:11 PM
ULM SCOTTCo-CEO and CIOJan 07Buy9.895,00049,47312,525Jan 07 12:06 PM
TickerELON [NASD]
CompanyEchelon Corporation
CountryUSA
IndustryNetworking & Communication Devices
Market Cap41.38MEPS (ttm)-0.36
P/E-EPS this Y-5.90%
Forward P/E-EPS next Y20.80%
PEG-EPS past 5Y14.50%
P/S1.07EPS next 5Y15.00%
P/B0.96EPS Q/Q-50.00%
Dividend-Sales Q/Q-23.20%
Insider Own0.50%Inst Own24.60%
Insider Trans0.00%Inst Trans3.97%
Short Float0.26%EarningsFeb 10/a
Analyst Recom3.00Target Price2.13
Avg Volume87.00K52W Range0.96 - 3.08
Mar-19-15 01:04PMECHELON CORP Financials
Mar-12-15 06:09AMECHELON CORP Files SEC form 10-K, Annual Report
Mar-02-15 09:08AMSXSW Panel: Network All the Things: What About Infrastructure? at noodls
Mar-02-15 09:00AMSXSW Panel: Network All the Things: What About Infrastructure? Business Wire
Feb-10-15 06:09PMEchelon reports 4Q loss AP
Feb-10-15 04:30PMEchelon Corp Earnings Call scheduled for 4:30 pm ET today
Feb-10-15 04:11PMECHELON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Feb-10-15 04:05PMEchelon Reports Fourth Quarter 2014 Results Business Wire
Feb-10-15 07:07AMQ4 2014 Echelon Corp Earnings Release - After Market Close
Echelon Corporation develops and markets energy control networking platforms. Its products enable everyday devices, including air conditioners, appliances, electricity meters, light switches, thermostats, and valves to be inter-connected. The company's building automation product portfolio include twisted-pair smart transceivers that can be embedded into building automation devices; embedded control and communications software; wired and wireless evaluation kits; SmartServer controller, a system manager and field controller for building networks and smart-energy applications; LonWorks control network software (LNS) and OpenLNS operating system development and integration tools that allows building owners to change service providers; and third party energy management or analytics software and applications. Its outdoor lighting product portfolio comprise power-line smart transceivers to embed into outdoor light ballasts, drivers, and generators; outdoor lighting controllers; motion sensors to turn outdoor lighting fixtures on and off based on motion; Smartserver controllers and gateways for connecting outdoor lighting segments to a service center; PL/RF Bridge to connect segments of outdoor lights to a SmartServer; wireless and Ethernet gateways to access network for setup functions, administration, and communications in the system; and management software and third-party system software to manage outdoor lighting network. It operates in the Americas; Europe, the Middle East, and Africa; and the Asia Pacific and Japan. The company markets its products and services to original equipment manufacturers and systems integrators in the building, industrial, transportation, utility/home, and other automation markets through direct sales organization, third-party electronics representatives, value-added resellers, and distributors. Echelon Corporation was founded in 1988 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDERSON Michael T.Sr. Vice PresidentMay 29Sale2.7125,00067,69541,843May 29 07:03 PM
TickerOPXA [NASD]
CompanyOpexa Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap15.58MEPS (ttm)-0.54
P/E-EPS this Y56.80%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-3.30%
P/S11.99EPS next 5Y-
P/B2.12EPS Q/Q25.00%
Dividend-Sales Q/Q0.00%
Insider Own9.97%Inst Own5.80%
Insider Trans0.00%Inst Trans-4.15%
Short Float1.30%EarningsFeb 26/a
Analyst Recom2.00Target Price4.00
Avg Volume327.87K52W Range0.59 - 1.94
Mar-18-15 04:31AMOpexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2015 at 4:00 PM ET at noodls
Mar-10-15 05:16PMMerck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
Mar-10-15 09:24AMOpexa Therapeutics Reports Year End 2014 Financial Results and Provides Corporate Update at noodls
Mar-10-15 09:00AMOpexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2015 at 4:00 PM ET Business Wire
Mar-09-15 07:13AMOpexa Therapeutics, Inc. Announces Record Date and Subscription Price for Rights Offering at noodls
Mar-09-15 07:13AMOpexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis at noodls
Mar-09-15 07:02AMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
Mar-09-15 07:00AMOpexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis Business Wire
Feb-27-15 01:04PMOPEXA THERAPEUTICS, INC. Financials
Feb-25-15 07:08PM10-K for Opexa Therapeutics, Inc. at Company Spotlight
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARABE TIMOTHY CDirectorSep 17Buy1.1510,00011,50016,000Sep 18 08:00 AM
Warma Neil KPresident & CEOSep 16Buy1.1110,00011,100107,634Sep 17 08:00 AM
TickerMDW [AMEX]
CompanyMidway Gold Corp.
CountryUSA
IndustryGold
Market Cap51.32MEPS (ttm)-0.15
P/E-EPS this Y117.60%
Forward P/E5.35EPS next Y77.42%
PEG-EPS past 5Y-38.00%
P/S-EPS next 5Y-
P/B0.73EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.30%Inst Own4.30%
Insider Trans1.95%Inst Trans8.86%
Short Float1.26%EarningsMar 12/a
Analyst Recom2.50Target Price-
Avg Volume682.25K52W Range0.31 - 1.17
Mar-27-15 07:34PMMidway Announces Planned Close of Public Comment for Draft EIS at Gold Rock Project, Nevada Business Wire
Mar-27-15 08:54AMMidway Pours First Gold at Pan Mine at noodls
Mar-27-15 08:30AMMidway Pours First Gold at Pan Mine Business Wire
Mar-21-15 01:04PMMIDWAY GOLD CORP Financials
Mar-19-15 08:45AMMidway Gold Slumps: MDW Falls 12.5% in Session - Tale of the Tape
Mar-18-15 11:24AMMIDWAY GOLD CORP Files SEC form 8-K, Regulation FD Disclosure
Mar-17-15 07:27AMMidway Gold Corp. (TSX and NYSE-MKT: MDW) (the "Company" or "Midway") announces financial results for the period ended December 31, 2014. at noodls
Mar-16-15 09:45PMMidway Announces 2014 Fourth Quarter Financial Results Business Wire
Mar-16-15 12:14PMMIDWAY GOLD CORP Files SEC form 10-K, Annual Report
Mar-06-15 02:17PMMIDWAY GOLD CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events
Midway Gold Corp. engages in the acquisition, exploration, and development of gold and silver mineral properties in North America. The company holds interest in the Pan and Gold Rock Projects located along the prolific Battle Mountain/Eureka gold trend; the Spring Valley property, which is located in the Spring Valley Mining District, Pershing County, Nevada. It also has interest in the Tonopah property, which is located in Nye County, Nevada; and the Golden Eagle property located in the Eureka mining district in Ferry County, Washington. The company was formerly known as Red Emerald Resource Corp. and changed its name to Midway Gold Corp. in July 2002. Midway Gold Corp. was founded in 1996 and is headquartered in Englewood, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sheridan John WilliamDirectorNov 10Buy0.8010,0008,00023,000Nov 12 01:14 PM
Brunk Kenneth ArnoldPresident & CEOJun 06Buy0.83120,482100,000189,482Jun 06 06:44 PM
TickerCLTX [NASD]
CompanyCelsus Therapeutics Plc
CountryUnited Kingdom
IndustryBiotechnology
Market Cap4.32MEPS (ttm)-1.80
P/E-EPS this Y90.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B0.89EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.11%Earnings-
Analyst Recom3.00Target Price-
Avg Volume183.54K52W Range0.80 - 7.00
Feb-18-15 03:02PMCelsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog Zacks
Feb-18-15 01:04PMCELSUS THERAPEUTICS PLC. Financials EDGAR Online Financials
Feb-17-15 05:02PMTransocean and Goodyear Tire are big market movers AP
Feb-17-15 04:30PMUS STOCKS-S&P 500 ends at record high on Greece hopes, as bonds drop Reuters
Feb-17-15 02:44PMUS STOCKS-Wall St edges up; S&P hits 2,100 on Greece hopes Reuters
Feb-17-15 12:49PMUS STOCKS-Wall St flat, paring losses on Greece hopes Reuters
Feb-17-15 11:56AMCelsus Therapeutics (CLTX) Stock Hits One-Year Low Following Disappointing Trial Results at TheStreet
Feb-17-15 11:26AMUS STOCKS-Wall St edges lower amid overseas issues; energy falls Reuters
Feb-17-15 09:57AMUS STOCKS-Wall St dips amid overseas concerns; energy weakens Reuters
Feb-17-15 08:58AMUS STOCKS-Futures point to flat open, major indexes at records Reuters
Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company's principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases. The company was formerly known as Morria Biopharmaceuticals Plc and changed its name to Celsus Therapeutics Plc in June 2013. Celsus Therapeutics Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
TickerONVO [AMEX]
CompanyOrganovo Holdings, Inc.
CountryUSA
IndustryMedical Laboratories & Research
Market Cap294.45MEPS (ttm)-0.36
P/E-EPS this Y-34.60%
Forward P/E-EPS next Y-2.80%
PEG-EPS past 5Y0.00%
P/S736.12EPS next 5Y-
P/B6.10EPS Q/Q-28.60%
Dividend-Sales Q/Q100.00%
Insider Own8.60%Inst Own24.70%
Insider Trans-Inst Trans23.98%
Short Float22.51%EarningsFeb 09/a
Analyst Recom3.00Target Price-
Avg Volume1.10M52W Range3.85 - 9.25
Mar-22-15 05:22PMEXCLUSIVE: Organovo CEO Keith Murphy Talks Pipeline, Market Misconceptions
Mar-19-15 05:02PMORGANOVO HOLDINGS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Mar-13-15 05:09PMORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-13-15 11:35AMOrganovo Soothes Spooked Market
Mar-13-15 08:16AMOrganovo Provides Market Update at noodls
Mar-13-15 08:05AMOrganovo Provides Market Update PR Newswire
Mar-06-15 08:22AMOrganovo Holdings, Inc.'s Presentations Now Available for On-Demand Viewing at VirtualInvestorConferences.com at noodls
Mar-06-15 08:00AMOrganovo Holdings, Inc.'s Presentations Now Available for On-Demand Viewing at VirtualInvestorConferences.com PR Newswire
Mar-06-15 08:00AMOrganovo Holdings, Inc.'s Presentations Now Available for On-Demand Viewing at VirtualInvestorConferences.com CNW Group
Mar-03-15 08:30AM5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at VirtualInvestorConferences.com CNW Group
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L'Oreal. The company was founded in 2007 and is headquartered in San Diego, California.
1 2 3 4 5 6 7 next